AbCellera closes $13 mln Series A financing led by DCVC Bio

AbCellera, a Vancouver-based developer of therapeutic antibodies, has raised close to $13 million (US$10 million) in a Series A financing. The round was led by DCVC Bio, a U.S. biotechnology venture capital firm. Managing Partner John Hamer joined the board. AbCellera was founded in 2012 based on technology created at the University of British Columbia. Its antibody discovery engine combines a range of innovations, including artificial intelligence and microfluidic screening technology. Led by CEO Carl Hansen, the company will use the funds raised for growth, including investments to build capacity and integration of advanced technological capabilities.

CanadaNorth AmericaBriefs